Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases
- 1 March 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 32 (3), 461-467
- https://doi.org/10.1097/pas.0b013e318157020e
Abstract
Aberrant diffuse expression of p63 in prostate carcinoma cells is a rare and poorly understood phenomenon. We studied 19 cases of prostate cancer with aberrant diffuse expression of p63 on needle biopsy and reviewed the subsequent radical prostatectomies in 6 cases. In 19/21 cases, 100% of the cancer nuclei stained intensely for p63, with 70% staining in the remaining 2 cases. Two additional radical prostatectomies with aberrant p63 staining with no needle biopsies available for review were also analyzed. On the hematoxylin and eosin-stained slides, 19/21 cases (90.5%) showed a distinctive morphology composed predominantly of glands, nests, and cords with atrophic cytoplasm, hyperchromatic nuclei, and visible nucleoli. Needle biopsy cases ranged from Gleason patterns 3 to 5 with tumor identified on one or more cores, ranging from a minute focus to 80% of the core. In all 8 radical prostatectomies p63 positive cancer was present, with in 2/8 cases both p63 positive cancer and usual p63 negative acinar prostate cancer. In all 8 cases, the tumors were organ confined with negative margins and there was no seminal vesicle involvement or lymph node metastasis. The presence of p63 positive atypical glands with an infiltrative pattern and perineural invasion on radical prostatectomy confirmed the needle biopsy diagnosis of carcinoma. Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation. The diagnosis of prostate cancer is based on the morphology and confirmed by the absence of high molecular weight cytokeratin staining and positivity for α-methylacyl-CoA racemase in the atypical glands. Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis.Keywords
This publication has 29 references indexed in Scilit:
- Spatial and Isoform Specific p63 Expression in the Male Human Urogenital TractJournal of Urology, 2006
- Comparison of annexin II, p63 and -methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray studyJournal of Clinical Pathology, 2006
- Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy SpecimensEuropean Urology, 2005
- p63/AMACR Antibody Cocktail Restaining of Prostate Needle Biopsy Tissues After Transfer to Charged SlidesAmerican Journal of Clinical Pathology, 2005
- P63 and p504s cocktail is useful in ambiguous lesions of the prostateHistopathology, 2004
- Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal CellsLaboratory Investigation, 2002
- Can Basal Cells Be Seen in Adenocarcinoma of the Prostate?The American Journal of Surgical Pathology, 2002
- p63The International Journal of Biochemistry & Cell Biology, 2002
- Rare Expression of High-Molecular-Weight Cytokeratin in Adenocarcinoma of the Prostate GlandThe American Journal of Surgical Pathology, 1999
- Keratin immunoreactivity in fine‐needle aspiration of the prostate: An aid in the differentiation of benign epithelium from well‐differentiated adenocarcinomaDiagnostic Cytopathology, 1988